In our cohort (n = 22), 5% of AML patients had higher expression of BCL11B mRNA, however 10 (45.5%) and 12 (54.5%) cases either expressed BCL11B protein or did not, respectively. This evidence concerns the gene BCL11B and acute myeloid leukemia.